Research Papers:

Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop

Francesco Gualdrini, Daisy Corvetta, Sandra Cantilena, Olesya Chayka, Barbara Tanno, Giuseppe Raschellà and Arturo Sala _

PDF  |  Supplementary Files  |  How to cite

Oncotarget. 2010; 1:278-288. https://doi.org/10.18632/oncotarget.138

Metrics: PDF 3790 views  |   ?  


Received: May 19, 2010, Accepted: July 16, 2010, Published: August 4, 2010

MYCN is a member of the MYC family of oncoproteins frequently amplified or overexpressed in aggressive, paediatric tumours of the nervous system. In this study we have identified the gene B-MYB, encoding the transcription factor also known as MYBL2, as a downstream target of MYCN. Using multiple in silico databases we show that expression of B-MYB significantly correlates with that of MYCN in neuroblastoma patients. MYCN binds to and activates the B-MYB gene in vivo and in vitro. Blunting B-MYB expression by RNA interference causes reduced proliferation of MYCN amplified, but not MYCN-non amplified, neuroblastoma cell lines, indicating that tumour cells are addicted to B-MYB in a MYCN dependent manner. Notably, B-MYB binds in vivo to the MYCN amplicon and is required for its expression. We conclude that MYCN and B-MYB are engaged in a reciprocal regulatory loop whose pharmacological targeting could be beneficial to patients with the aggressive forms of cancer in which MYCN is amplified.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 138